Reduction of MHC-I expression limits T-lymphocyte-mediated killing of Cancer-initiating cells
Brian J. Morrison(University of Miami), John C. Morris(Alzheimer's Association)
Cited by 131
Related Papers
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck
|JAMA Oncology|2018|111
Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
|Frontiers in Oncology|2021|26
Does prior dengue virus exposure worsen clinical outcomes of Zika virus infection? A systematic review, pooled analysis and lessons learned
|PLoS neglected tropical diseases|2019|23
Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
|Journal of Clinical Oncology|2019|8
Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors
|Asian Pacific Journal of Cancer Prevention|2019|6